These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24958324)

  • 21. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients.
    Masuda TA; Kataoka A; Ohno S; Murakami S; Mimori K; Utsunomiya T; Inoue H; Tsutsui S; Kinoshita J; Masuda N; Moriyama N; Mori M
    Int J Oncol; 2005 Mar; 26(3):721-30. PubMed ID: 15703829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients.
    Farmen RK; Nordgård O; Gilje B; Shammas FV; Kvaløy JT; Oltedal S; Heikkilä R
    Breast Cancer Res Treat; 2008 Mar; 108(2):251-8. PubMed ID: 17492378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
    von Minckwitz G; Möbus V; Schneeweiss A; Huober J; Thomssen C; Untch M; Jackisch C; Diel IJ; Elling D; Conrad B; Kreienberg R; Müller V; Lück HJ; Bauerfeind I; Clemens M; Schmidt M; Noeding S; Forstbauer H; Barinoff J; Belau A; Nekljudova V; Harbeck N; Loibl S
    J Clin Oncol; 2013 Oct; 31(28):3531-9. PubMed ID: 23980081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positive bone marrow biopsy is associated with a decreased disease-free survival in patients with operable breast cancer.
    Fortunato L; Mascaro A; Baldi A; Farina M; Cortese G; Ventrone MA; Amini M; Vitelli C
    Ann Surg Oncol; 2009 Nov; 16(11):3010-9. PubMed ID: 19641970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer.
    Kuniyoshi RK; Gehrke Fde S; Alves BC; Vilas-Bôas V; Coló AE; Sousa N; Nunes J; Fonseca FL; Del Giglio A
    Tumour Biol; 2015 Sep; 36(10):8075-83. PubMed ID: 25976504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiplex PCR-based detection of circulating tumor cells in lung cancer patients using CK19, PTHrP, and LUNX specific primers.
    Katseli A; Maragos H; Nezos A; Syrigos K; Koutsilieris M
    Clin Lung Cancer; 2013 Sep; 14(5):513-20. PubMed ID: 23810363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR.
    Koga T; Tokunaga E; Sumiyoshi Y; Oki E; Oda S; Takahashi I; Kakeji Y; Baba H; Maehara Y
    Hepatogastroenterology; 2008; 55(84):1131-5. PubMed ID: 18705345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy.
    Solá M; Margelí M; Castellá E; Cirauqui B; Mariscal A; Rull M; Julian JF; Luna M; Vallejo V; Fraile M
    Breast; 2013 Oct; 22(5):908-13. PubMed ID: 23683695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
    Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
    Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ESPL1 is a candidate oncogene of luminal B breast cancers.
    Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
    Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CTCs in primary breast cancer (II).
    Saloustros E; Mavroudis D
    Recent Results Cancer Res; 2012; 195():187-92. PubMed ID: 22527506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer.
    Tengström M; Mannermaa A; Kosma VM; Hirvonen A; Kataja V
    Anticancer Res; 2014 Jun; 34(6):3031-7. PubMed ID: 24922669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
    Bozionellou V; Mavroudis D; Perraki M; Papadopoulos S; Apostolaki S; Stathopoulos E; Stathopoulou A; Lianidou E; Georgoulias V
    Clin Cancer Res; 2004 Dec; 10(24):8185-94. PubMed ID: 15623593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Detection and prognostic significance of micrometastasis in peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation therapy].
    Chen TF; Jiang GL; Zhang YQ; Wang LJ; Fu XL; Qian H; Wu KL; Zhao S
    Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):365-8. PubMed ID: 17892133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes.
    Stathopoulos EN; Sanidas E; Kafousi M; Mavroudis D; Askoxylakis J; Bozionelou V; Perraki M; Tsiftsis D; Georgoulias V
    Ann Oncol; 2005 Feb; 16(2):240-6. PubMed ID: 15668277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: significance of the prediction of postoperative metastasis.
    Wang JY; Wu CH; Lu CY; Hsieh JS; Wu DC; Huang SY; Lin SR
    World J Surg; 2006 Jun; 30(6):1007-13. PubMed ID: 16736329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.